T1	Participants 520 566	SR patients (localized tumors, volume <100 mL)
T2	Participants 1161 1347	647 patients were randomly assigned: 79 SR patients were assigned to VAIA, 76 SR patients were assigned to VACA, 240 HR were assigned to VAIA, and 252 HR patients were assigned to EVAIA.
